The Patent Trial and Appeal Board has upheld a patent covering Akorn Inc.’s glaucoma medication Zioptan, following an inter partes review in which the board pressed forward despite the challenger backing out.
Residents of a Chicago suburb have urged an Illinois federal judge to send back to state court three lawsuits over claims that sterilization company Sterigenics knowingly emitted cancerous chemicals from a local facility for decades without disclosing the risks, saying their suits don't implicate the Clean Air Act, only state law claims.
The billionaire founder and former chairman of Insys Therapeutics Inc. cannot withhold company documents from federal prosecutors seeking to prove a conspiracy to bribe doctors to prescribe fentanyl-based drugs just because he happens to be in possession of them, the government said Thursday.
Boston federal prosecutors requested a five-month prison sentence Thursday for the former chairman of a small California biotechnology company who took a plea deal after his trial on allegations of lying to the U.S. Securities and Exchange Commission ended in a hung jury.
The Judicial Panel on Multidistrict Litigation appeared disinclined Thursday to create a new MDL for “opioid babies” whose mothers used prescription narcotics, sharply questioning whether such a move would actually expedite the infants’ suits.
In a precedential decision clarifying the reach and authority of bankruptcy courts, the Third Circuit on Wednesday upheld a Delaware bankruptcy judge’s finding in 2012 that his court lacked jurisdiction to transfer a liquidating trustee’s adversary proceeding to a district court in Pennsylvania.
Mylan Inc. and other generic drug companies have asked the U.S. Supreme Court to review a Federal Circuit decision that upheld a UCB Inc. patent on epilepsy drug Vimpat, telling the justices UCB has been allowed to patent the same invention twice.
A former Zimmer Biomet Holdings Inc. executive wasn’t eligible for severance or stock options when she left the medical device manufacturer, as she failed to prove that her resignation fell under a carve-out in her employment contract, an Indiana federal judge has ruled as part of a sex discrimination suit.
Two international tax attorneys were hit with criminal charges and a civil complaint by the U.S. Securities and Exchange Commission in Massachusetts federal court in connection with multiple multimillion-dollar pump-and-dump schemes, officials said Tuesday.
Mylan Pharmaceuticals has urged a New Jersey federal judge to allow it to add three consumer witnesses in its case accusing Celgene Corp. of stifling generic competition for the brand-name cancer drugs Thalomid and Revlimid, saying they can testify about the scheme's impact on drug prices.
AbbVie Inc. urged an Illinois federal judge on Tuesday to toss a proposed class action over a corrective disclosure released after a stock buyback effort that shareholders said cost them $100 million, arguing that the investors failed to make any adequate fraud or negligence claims.
Cyrus Capital Partners could team up with the Sears chairman’s hedge fund to bid for Sears, Murphy Oil Corp. is reportedly discussing a deal to sell Malaysian oil and gas assets, and Unilever is the leading bidder for GlaxoSmithKline’s Indian consumer health unit.
A medical technology business is seeking a rehearing en banc at the D.C. Circuit after a panel affirmed that a $400 million arbitral award the company secured against the Czech Republic Ministry of Health was not enforceable, asserting the ruling conflicts with standards for confirmation laid out by other circuit decisions.
Rochester Drug Cooperative won’t be able to dodge questions about a federal investigation into opioid sales during upcoming depositions in its proposed class action accusing Actavis LLC and Shire LLC of settling a patent dispute over an ADHD drug on anti-competitive terms, a Massachusetts federal judge ruled Tuesday.
The U.S. Food and Drug Administration on Wednesday approved Celltrion and Teva’s version of the blockbuster cancer treatment Rituxan, marking the first biosimilar approved in the U.S. to treat non-Hodgkin’s lymphoma.
Massachusetts-based biopharmaceutical firm Moderna Inc. on Wednesday said it expects to bring in $500 million at the midpoint of its price range for its upcoming initial public offering, led by Goodwin Procter LLP.
The Federal Circuit’s extension of a so-called unclean hands defense to wipe out a $200 million patent verdict Merck won against Gilead over hepatitis C drugs after a Merck in-house attorney purportedly exhibited "dishonest and duplicitous" behavior conflicts with U.S. Supreme Court precedent, Merck told the high court Tuesday.
Generics makers Roxane and Teva urged the full Federal Circuit Tuesday not to rehear a decision invalidating four Acorda patents on the multiple sclerosis drug Ampyra, arguing that the ruling was a careful application of the so-called blocking patent doctrine, not an expansion of it.
The former vice president of sales at Insys Therapeutics pled guilty to racketeering conspiracy in Boston federal court Wednesday, saying he would help prosecutors in their case against his bosses and subordinates for allegedly bribing doctors to prescribe dangerous fentanyl-based painkillers.
A Delaware federal court has granted Eli Lilly and Co.’s request to stay an antitrust suit brought by Eagle Pharmaceuticals Inc., saying that waiting until a related patent infringement case is resolved would simplify things.
Artificial intelligence is already in use for applications like calculating drug dosages for cancer patients. But future uses of AI could range much further, perhaps even as depicted in TV shows like "Westworld." We are only beginning to grapple with how the law will treat liability issues raised by such technological advances, says Ileana Blanco of DLA Piper LLP.
By combining effective education, prevention, behavioral health care and evidence-based treatment, health insurance providers are making real progress in the fight against opioid addiction, says Matthew Eyles of America's Health Insurance Plans.
While testifying before the Senate's antitrust subcommittee earlier this month, the chairman of the Federal Trade Commission and the head of the U.S. Department of Justice Antitrust Division provided additional detail about several of the agencies’ initiatives, say attorneys with Paul Weiss Rikfind Wharton & Garrison LLP.
The process of applying for litigation financing isn’t difficult, but few do it right the first time. Following five steps in your application process will help make sure litigation funders are convinced of the value of your company's legal claims, says Molly Pease of Curiam Capital LLC.
A New Jersey federal court's decision in Cotto v. Ardagh — the first case to evaluate the employment rights of medical marijuana users in the state — provides persuasive authority that private employers are not obligated to waive or relax their drug testing requirements, say Jill Vorobiev and Melissa Ferrara of Reed Smith LLP.
The Democratic Party is expected to take control of the House of Representatives next year, which will dramatically increase the congressional investigations risks for the private sector. Prime targets include pharmaceutical, financial services and technology companies, says Brian Smith of Covington & Burling LLP.
Secondary considerations can be a useful tool for patent owners attempting to overcome an obviousness challenge. However, the Federal Circuit's decision last month in Acorda v. Roxane leaves the treatment of secondary considerations in question when a so-called “blocking patent” may exist, say Daniel Winston and Bryana McGillycuddy of Choate Hall & Stewart LLP.
In an era when law firms are fighting for business and clients can dictate the terms of the relationship, "value" has become a moving target. Firms that take a proactive approach by using strategies designed to articulate value over time will gain the competitive advantage, says Dan Tacone at Intapp Inc.
In this monthly series, Amanda Brady of Major Lindsey & Africa interviews management from top law firms about the increasingly competitive business environment. Here we feature Pier D'Angelo, chief pricing and practice officer at Allens.
The Committee on Foreign Investment in the United States has announced a pilot program to review noncontrolling foreign investments in certain U.S. industries that were formerly outside the scope of its jurisdiction. This is a rapid assertion of CFIUS' new powers under the Foreign Investment Risk Review Modernization Act, say attorneys with Ropes & Gray LLP.